RSPH Invesco S&P 500 Equal Weight Health Care ETF

Invesco S&P 500 Equal Weight Health Care ETF (RSPH) currently reports 59 stock positions (subject to change), placing it in the neither concentrated nor index-like range by holdings breadth. The top line-up is TECH (2.19%), MRNA (1.98%), CRL (1.97%), with TECH as the largest single weight at 2.19%. Together, the top three holdings account for 6.14%, which indicates that idiosyncratic risk at the top of the book is relatively contained within the overall portfolio. The resulting profile combines thematic conviction with varying degrees of diversification, which can support upside participation while still spreading idiosyncratic risk beyond the top weights.

From a returns-on-capital standpoint, ROIC is 17.85%, WACC is 7.72%, and the economic spread is 10.12%. On balance, holdings are generating returns that comfortably clear their cost of capital, a reliable indicator of competitive durability. Supporting metrics show ROE at 21.67% and ROA at 7.04%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a portfolio with credible compounding capacity if current operating execution persists.

The market currently prices the portfolio at trailing P/E of 20.35, forward P/E of 16.99, PEG of 2.19. The gap between P/E and forward P/E is small, suggesting the valuation is not contingent on a near-term earnings step-change. The PEG ratio is consistent with a portfolio that is reasonably valued on a growth basis — not cheap, but not obviously expensive either. The aggregate current ratio of 1.83 points to adequate liquidity across holdings. Valuation and liquidity together frame a portfolio where the price paid today is a reasonable bet on earnings delivery — but not a margin-of-safety purchase at current levels.

On profitability at each income statement layer, gross margin sits at 46.41%, operating margin at 11.87%, and free cash flow margin at 15.97%. The portfolio's gross margins are solid, reflecting a reasonable balance between revenue realization and direct cost absorption. The operating margin reading is modest, consistent with businesses still working to scale their cost structures efficiently. Free cash flow margins are strong, reflecting capital-efficient businesses that largely self-fund their growth. Taken together, the margin stack suggests quality that is uneven — some layers are more resilient than others, and that asymmetry matters under stress.

Looking at what the businesses are actually delivering versus what analysts are pricing in, TTM revenue growth of 15.42% indicating top-line growth that is constructive without being speculative. At the same time, the estimated 12-month price change of 9.44%, where consensus pricing points to a narrow upside range. Revenue growth captures operating momentum, while price targets reflect external expectations that can move with rates, risk appetite, and sector sentiment. Whether current momentum translates into delivered returns will depend on the durability of both top-line trends and the assumptions embedded in analyst targets. The estimated 12-month price change is a weighted composite of analyst price target estimates adjusted by each holding's ETF weight, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.

Putting the pieces together, this is a profile with genuine merit: the numbers support confidence in the forward case without requiring heroic assumptions.

The views expressed above are derived from quantitative data only and should not be relied upon as financial advice. Investment decisions should be based on your own research and risk tolerance.